文章摘要
Albert Kimutai,Willy K. Tonui,Michael M. Gicheru,Peter Kamau Ngure,Johnstone Ingonga,Stella Kepha,Laban Ireri Njeru,Dorcas Wachira,Robert Karanja Muhia,Milkah Mwangi,Lydia B. Nyamwamu.[J].南京医科大学学报,2009,29(6):359~372
Evaluation of the adjuvanticity of artemisinin with soluble Leishmania major antigens in BALB/c mice
投稿时间:2009-08-20  
DOI:10.7655
中文关键词: 
英文关键词: Artemisinin  Leishmania  Soluble Leishmania antigens  BALB/c mice  immunity  cytokine  adjuvant  interleukin-4 (IL-4)  IL-5  IFN-γ  lesion size  footpad lesion  vaccine  parasite burden  proliferation  stimulation index
基金项目:
作者单位
Albert Kimutai Department of Zoological Sciences, Kenyatta University, Nairobi 43844, Kenya 
Willy K. Tonui Centre for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi 54844-00200, Kenya 
Michael M. Gicheru Department of Zoological Sciences, Kenyatta University, Nairobi 43844, Kenya 
Peter Kamau Ngure Centre for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi 54844-00200, Kenya 
Johnstone Ingonga Centre for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi 54844-00200, Kenya 
Stella Kepha School of Biological Sciences, University of Nairobi, Nairobi 30197-00100, Kenya 
Laban Ireri Njeru Department of Zoological Sciences, Kenyatta University, Nairobi 43844, Kenya 
Dorcas Wachira Centre for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi 54844-00200, Kenya 
Robert Karanja Muhia Centre for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi 54844-00200, Kenya 
Milkah Mwangi Centre for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi 54844-00200, Kenya 
Lydia B. Nyamwamu Department of Zoological Sciences, Kenyatta University, Nairobi 43844, Kenya 
摘要点击次数: 1857
全文下载次数: 267
中文摘要:
      
英文摘要:
      Objective: To determine the adjuvant potential of artemisinin with a soluble leishmanial antigen in vaccinating BALB/c mice.Methods: Seventy two female BALB/c mice were randomly assigned into six groups. The mice were vaccinated with soluble Leishmania antigens (SLA) alone, artemisinin co-administered with SLA, SLA and Bacille Calmette Guérin (BCG) vaccine, and artemisinin and BCG alone. Unvaccinated mice formed the control group. The induction of cell-mediated immunity following vaccination was determined by measuring in vitro lymphocyte proliferation and the production of interleukin (IL)-4, IL-5 and gamma interferon (IFN-γ) determined by flow cytometry. Protection against L. major was determined by quantifying parasite burdens in L. major infected footpads using a limiting dilution assay and by measuring lesion sizes of the infected footpad compared to the contralateral uninfected footpad. Results: Mice receiving SLA plus artemisinin produced significantly high levels of IL-4 and IL-5 (P < 0.05) and low levels of IFN-γ, resulting in exacerbated disease. In addition, subcutaneous administration of SLA + artemisinin, artemisinin alone or SLA alone resulted in the development of large footpad swellings and high parasite loads that were comparable to those of the control unvaccinated mice (P > 0.05), resulting in exacerbated disease. Conclusion: These data suggest that artemisinin is not a suitable adjuvant for Leishmania vaccines. However, since artemisinin has been shown to be effective against Leishmania parasites in vitro and in vivo, further studies ought to be conducted to determine its immunochemotherapeutic potential when co-administered with Leishmania antigens.
查看全文   查看/发表评论  下载PDF阅读器
关闭